Atlas Molecular Pharma — Series A · €3M

Atlas Molecular Pharma, a CIC bioGUNE spin-off based in Derio (Bizkaia), raised €3 million co-led by Inveready (through Inveready Biotech III), CDTI and the Basque fund EZTEN FCR, with existing shareholders also taking part. The capital funds Phase I and Phase II clinical trials in the US of ATL-001, a pharmacological chaperone for congenital erythropoietic porphyria.